These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9030238)

  • 1. [Introduction of anticancer agents to phase I clinical trials].
    Shimoyama M
    Gan To Kagaku Ryoho; 1997 Jan; 24(2):246-55. PubMed ID: 9030238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Guideline for phase I study on new anticancer agents].
    Shimoyama M
    Gan To Kagaku Ryoho; 2001 Feb; 28(2):261-70. PubMed ID: 11242659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current status and issues in clinical trials of anticancer agents].
    Kojima H
    Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():295-301. PubMed ID: 7986107
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Phase I clinical trial design of anticancer agents--a Fibonacci and a modified Fibonacci sequence].
    Kusaba H; Tamura T
    Gan To Kagaku Ryoho; 2000 May; 27(5):775-8. PubMed ID: 10832451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Continual reassessment method (CRM)].
    Ishizuka N
    Gan To Kagaku Ryoho; 2000 Aug; 27(9):1449-57. PubMed ID: 10969605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Some ethical issues in phase II trials in acute leukemia.
    Thall PF; Estey EH
    Clin Adv Hematol Oncol; 2005 Dec; 3(12):943-8. PubMed ID: 16555436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Challenge of Developing New Therapies for Childhood Cancers.
    Balis FM
    Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translation of innovative designs into phase I trials.
    Rogatko A; Schoeneck D; Jonas W; Tighiouart M; Khuri FR; Porter A
    J Clin Oncol; 2007 Nov; 25(31):4982-6. PubMed ID: 17971597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Principles and practice of clinical phase I studies].
    Hanauske AR
    Onkologie; 2008; 31 Suppl 2():39-45. PubMed ID: 18487868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New designs for phase II trials: application to a trial of targeted therapies vs. chemotherapy in patients age > 60 with AML/high-risk MDS.
    Estey EH
    Ann Hematol; 2004; 83 Suppl 1():S94-6. PubMed ID: 15124692
    [No Abstract]   [Full Text] [Related]  

  • 12. [The strategy of combination phase I/II study].
    Murakami H; Ohe Y; Saijo N
    Gan To Kagaku Ryoho; 2000 Nov; 27(13):2151-4. PubMed ID: 11103251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I cancer trials: limitations and implications.
    Dillman RO; Koziol JA
    Mol Biother; 1992 Sep; 4(3):117-21. PubMed ID: 1445664
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endpoints and other considerations in phase I studies of targeted anticancer therapy: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies (MDICT).
    Booth CM; Calvert AH; Giaccone G; Lobbezoo MW; Seymour LK; Eisenhauer EA
    Eur J Cancer; 2008 Jan; 44(1):19-24. PubMed ID: 17890079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Accelerated titration design].
    Minami H
    Gan To Kagaku Ryoho; 2000 Sep; 27(10):1601-7. PubMed ID: 11016010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient specific dosing in a cancer phase I clinical trial.
    Babb JS; Rogatko A
    Stat Med; 2001 Jul; 20(14):2079-90. PubMed ID: 11439422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesyltransferase and geranylgeranyltransferase I inhibitors and cancer therapy: lessons from mechanism and bench-to-bedside translational studies.
    Sebti SM; Hamilton AD
    Oncogene; 2000 Dec; 19(56):6584-93. PubMed ID: 11426643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Principle and practice of clinical phase III studies].
    Morant R
    Onkologie; 2008; 31 Suppl 2():53-7. PubMed ID: 18487870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Commentary on "European collaboration in trials of new agents for children with cancer" by Ablett et al.
    Smith MA; Anderson BD
    Eur J Cancer; 2004 Aug; 40(12):1893-5. PubMed ID: 15288292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.